- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04880187
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
September 7, 2022 updated by: Axcella Health, Inc
A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fibrosis (EMMPACT)
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH).
as well as the safety and tolerability of AXA1125.
Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
273
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Margaret Koziel, MD
- Phone Number: (857) 320-3200
- Email: clinicaltrials@axcellahealth.com
Study Locations
-
-
-
Bedford Park, Australia
- Recruiting
- Flinders Medical Centre
-
Brisbane, Australia
- Recruiting
- Royal Brisbane and Women'S Hospital
-
Clayton, Australia
- Recruiting
- Monash Medical Centre
-
Concord, Australia
- Recruiting
- Concord Repatriation General Hospital
-
Murdoch, Australia
- Recruiting
- Fiona Stanley Hospital
-
-
-
-
-
Halifax, Canada
- Recruiting
- Nova Scotia Health Authority
-
-
Alberta
-
Calgary, Alberta, Canada
- Recruiting
- University of Calgary Liver Unit
-
-
Ontario
-
London, Ontario, Canada
- Recruiting
- LMC Diabetes & Endocrinology Ltd
-
Toronto, Ontario, Canada, M6H 3M1
- Recruiting
- Toronto Liver Centre
-
-
-
-
-
La Tronche, France
- Recruiting
- CHU Grenoble-Alpes - Hopital Michallon
-
Lyon, France
- Recruiting
- Hôpital de la Croix Rousse - HCL
-
Montpellier, France
- Recruiting
- CHU DE MONTPELLIER - Hopital Saint Eloi
-
Paris, France
- Recruiting
- AP-HP Hopital Saint Antoine
-
Pessac, France
- Recruiting
- CHU Bordeaux - Hopital Haut-Leveque
-
Villejuif, France
- Recruiting
- AP-HP Hopital Paul Brousse
-
-
-
-
CET
-
Myslowice, CET, Poland
- Recruiting
- ID Clinic
-
-
-
-
-
San Juan, Puerto Rico
- Recruiting
- Fundacion de Investigacion (FDI)
-
-
-
-
-
London, United Kingdom
- Recruiting
- King's College Hospital
-
-
-
-
Alabama
-
Cullman, Alabama, United States, 35055
- Recruiting
- Cullman Clinical Trials
-
-
Arizona
-
Tucson, Arizona, United States, 85712
- Recruiting
- Adobe Clinical Research, LLC
-
Tucson, Arizona, United States, 85715
- Recruiting
- Del Sol Research Management, LLC
-
-
California
-
Canoga Park, California, United States, 91304
- Recruiting
- San Fernando Valley Health Institute
-
Gardena, California, United States, 90247
- Recruiting
- National Research Institute
-
Huntington Park, California, United States, 90255
- Recruiting
- National Research Institute
-
Lancaster, California, United States, 93534
- Recruiting
- Om Research LLC
-
Los Angeles, California, United States, 90057
- Recruiting
- National Research Institute
-
Rialto, California, United States, 92377
- Recruiting
- Inland Empire Liver Foundation
-
San Diego, California, United States, 92114
- Recruiting
- Precision Research Institute, LLC
-
-
Florida
-
Boca Raton, Florida, United States, 33434
- Recruiting
- Excel Medical Clinical Trials, LLC
-
Bradenton, Florida, United States, 34208
- Recruiting
- Synergy Healthcare
-
Clearwater, Florida, United States, 33761
- Recruiting
- Tampa Bay Medical Research , Inc.
-
Hialeah Gardens, Florida, United States, 33016
- Recruiting
- Evolution Clinical Trials, Inc.
-
Jacksonville, Florida, United States, 32256
- Recruiting
- ENCORE Borland Groover Clinical Research
-
Jacksonville, Florida, United States, 32205
- Recruiting
- Westside Center for Clinical Research
-
Maitland, Florida, United States, 32751
- Recruiting
- ClinCloud LLC
-
Miami, Florida, United States, 33014-3616
- Recruiting
- Clinical Pharmacology of Miami, LLC
-
Miami, Florida, United States, 33155
- Recruiting
- La Salud Research
-
Miami, Florida, United States, 33173
- Recruiting
- Genoma Research Group, Inc
-
Miami Lakes, Florida, United States, 33014
- Recruiting
- Panax Clinical Research
-
Ocoee, Florida, United States, 34761
- Recruiting
- Sensible Healthcare, LLC
-
Pinellas Park, Florida, United States, 33709
- Recruiting
- Theia Clinical Research, LLC
-
Port Orange, Florida, United States, 32124
- Recruiting
- Progressive Medical Research
-
Viera, Florida, United States, 32940
- Recruiting
- ClinCloud, LLC
-
West Palm Beach, Florida, United States, 33401
- Recruiting
- Metabolic Research Institute, Inc.
-
Winter Park, Florida, United States, 32789
- Recruiting
- Conquest Research
-
-
Indiana
-
Hammond, Indiana, United States, 46324
- Recruiting
- ASHA Clinical Research
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University (IU) School of Medicine
-
-
Louisiana
-
Bastrop, Louisiana, United States, 71201
- Recruiting
- Delta Research Partners
-
Marrero, Louisiana, United States, 70072
- Recruiting
- Tandem Clinical Research
-
Metairie, Louisiana, United States, 70006
- Recruiting
- Tandem Clinical Research GI
-
Shreveport, Louisiana, United States, 71105
- Recruiting
- Louisiana Research Center, LLC
-
-
Mississippi
-
Biloxi, Mississippi, United States, 39532
- Recruiting
- The National Diabetes & Obesity Research Institute
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Recruiting
- Sierra Clinical Research
-
Las Vegas, Nevada, United States, 89106
- Recruiting
- Jubilee Clinical Research, Inc.
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
New York, New York, United States, 10033
- Recruiting
- Tandem Clinical Research GI
-
-
North Carolina
-
Morehead City, North Carolina, United States, 28557
- Recruiting
- Lucas Research - Diabetes & Endocrinology Consultants, PC
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- Consultants for Clinical Research
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Recruiting
- Rapid City Medical Center
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- Recruiting
- ClinSearch LLC
-
-
Texas
-
Arlington, Texas, United States, 76012
- Recruiting
- Texas Clinical Research Institute
-
Austin, Texas, United States, 78757
- Recruiting
- Pinnacle Clinical Research
-
Austin, Texas, United States, 78757
- Recruiting
- American Research Corporation
-
Houston, Texas, United States, 77099
- Recruiting
- Pioneer Research Solutions Inc.
-
Katy, Texas, United States, 77494
- Recruiting
- R & H Clinical Research
-
Red Oak, Texas, United States, 75154
- Recruiting
- Epic Medical Research
-
San Antonio, Texas, United States, 78229
- Recruiting
- Pinnacle Clinical Research
-
San Antonio, Texas, United States, 78229
- Recruiting
- Endeavor Clinical Trials
-
San Antonio, Texas, United States, 78215
- Recruiting
- American Research Corporation
-
Stafford, Texas, United States, 77477
- Recruiting
- R & H Clinical Research
-
Sugar Land, Texas, United States, 77478
- Recruiting
- Simcare Medical Research, LLC
-
Waco, Texas, United States, 76710
- Recruiting
- Impact Clinical Research
-
-
Utah
-
Riverton, Utah, United States, 84065
- Recruiting
- Velocity - Advanced Clinical Research - Salt Lake City of Gastroenterolog
-
-
Virginia
-
Manassas, Virginia, United States, 20110
- Recruiting
- Manassas Clinical Research Center
-
Richmond, Virginia, United States, 23298
- Recruiting
- Virginia Commonwealth University Medical College of Virginia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing to participate in the study and provide written informed consent.
- Male and female adults aged > 18 years.
- Must have NASH and fibrosis on a liver biopsy sample
- If a historical liver biopsy is used for Screening, obtained within 6 months prior to Screening;
- Subjects may have a diagnosis of T2DM
Exclusion Criteria:
- History or presence of liver disease (other than NAFLD or NASH)
- History or presence of cirrhosis and/or history or presence of hepatic decompensation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AXA1125 33.9g
33.9 g AXA1125 administered orally BID with or without food
|
AXA1125 administered BID with or without food
|
Placebo Comparator: Placebo
Matching Placebo administered orally BID with or without food
|
Matching Placebo administered BID with or without food
|
Experimental: AXA1125 22.6g
22.6 g AXA1125 administered orally BID with or without food
|
AXA1125 administered BID with or without food
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in steatohepatitis
Time Frame: Baseline to Week 48
|
2-point improvement from baseline to Week 48 in the non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) based on a scale from 0-8 with 0 being no NASH and 8 being the highest score
|
Baseline to Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resolution of NASH without worsening of fibrosis
Time Frame: Baseline to week 48
|
The proportion of subjects with resolution of NASH with no worsening of fibrosis defined as a post-treatment ballooning score of 0 and an inflammation score of 0 or 1 on liver biopsy.
|
Baseline to week 48
|
Improvement of fibrosis by one stage without worsening of NASH
Time Frame: Baseline to week 48
|
The proportion of subjects who have at least a 1-stage improvement in fibrosis and no worsening of NASH based on liver biopsy 0 being no fibrosis and 4 being the worse.
|
Baseline to week 48
|
Incidence of study drug emergent adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Baseline to week 48
|
Baseline to week 48
|
|
Change from baseline in liver stiffness as measured by vibration controlled transient elastography (Fibroscan™)
Time Frame: Baseline to week 48
|
Baseline to week 48
|
|
Change from baseline in hepatic fat as measured by MRI
Time Frame: Baseline to week 48
|
Baseline to week 48
|
|
Change from baseline in measures of glucose control as determined by glycated hemoglobin (HbA1c)
Time Frame: Baseline to week 48
|
Baseline to week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stephen Harrison, MD, Pinnacle Clinical Research
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2021
Primary Completion (Anticipated)
September 1, 2023
Study Completion (Anticipated)
October 1, 2023
Study Registration Dates
First Submitted
May 3, 2021
First Submitted That Met QC Criteria
May 7, 2021
First Posted (Actual)
May 10, 2021
Study Record Updates
Last Update Posted (Actual)
September 8, 2022
Last Update Submitted That Met QC Criteria
September 7, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AXA1125-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Alcoholic Steatohepatitis (NASH)
-
Corcept TherapeuticsRecruitingNon-alcoholic Steatohepatitis (NASH)United States
-
Novartis PharmaceuticalsTerminatedNon-alcoholic Steatohepatitis (NASH)Belgium, Germany, Taiwan, Austria, United States, Spain, Korea, Republic of, Argentina, Australia, Italy, Japan, Singapore, Netherlands, Slovakia, France, Canada, India
-
Immuron Ltd.CompletedNon-alcoholic Steatohepatitis (NASH)United States, Australia, Israel
-
EccogeneRecruiting
-
Guangdong Raynovent Biotech Co., LtdCompletedNon-Alcoholic Steatohepatitis (NASH)China
-
Novartis PharmaceuticalsTerminatedNon-alcoholic Steatohepatitis NASHUnited Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
-
Hoffmann-La RocheCompletedNon-Alcoholic Steatohepatitis (NASH)France
-
University of ZurichCompletedNon-alcoholic Steatohepatitis (NASH)Switzerland
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingNon-Alcoholic Steatohepatitis (NASH)China
-
AstraZenecaActive, not recruitingNon-alcoholic Steatohepatitis (NASH)United States
Clinical Trials on AXA1125
-
Axcella Health, IncCompleted
-
Axcella Health, IncCompletedPost-Acute Sequelae of SARS-CoV-2 (PASC) InfectionUnited Kingdom